Table. Baseline Clinical Characteristics.
| Characteristic | Patients, No. (%)a | ||
|---|---|---|---|
| Surgery RCT (n = 971) | TAVI RCT (n = 1128) | TAVI non-RCT (n = 2663)b | |
| Age, mean (SD), y | 80.6 (6.3) | 80.9 (6.5) | 83.1 (8.0)c |
| Sex | |||
| Female | 444 (45.7) | 496 (44.0) | 1217 (45.7) |
| Male | 527 (54.3) | 632 (56.0) | 1446 (54.3) |
| Body surface area, mean (SD), m2 | 1.9 (0.2) | 1.9 (0.2) | 1.9 (0.3)c |
| STS-PROM, mean (SD)d | 5.3 (2.5) | 5.2 (2.4) | 8.7 (4.6)c |
| NYHA HF class III/IV | 639 (65.8) | 757 (67.1) | 2288 (85.9)c |
| Prior percutaneous coronary intervention | 253 (26.1) | 280 (24.8) | 1052 (39.5)c |
| Prior coronary artery bypass surgery | 213 (21.9) | 229 (20.3) | 973 (36.5)c |
| Hypertension | 889 (91.6) | 1056 (93.6) | 2458 (92.3) |
| Creatinine >2.0 mg/dL | 24 (2.5) | 24 (2.1) | 121 (4.5)c |
| Prior atrial fibrillation/flutter | 305 (31.4) | 348 (30.9) | 1132 (42.6)c |
| Baseline anticoagulation therapy | 236 (24.3) | 236 (20.9) | 558 (21.0) |
Abbreviations: HF, heart failure; NYHA, New York Heart Association; RCT, randomized clinical trial; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI, transcatheter aortic valve implantation.
SI conversion factor: To convert creatinine to μmol/L, multiply by 88.4.
a
There were no significant differences between the surgery and TAVI RCT populations.
b
The non-RCT TAVI cohort comprises the pooled CoreValve US Extreme Risk and the CoreValve CAS populations.
c
P < .001 vs TAVI RCT.
d
STS-PROM provides an estimate of the risk of death at 30 days among patients undergoing surgical aortic valve replacement based on several demographic and procedural variables.